Financial Results – Ind-AS |
| Particulars | 3 months/ 6 months ended
(dd-mm-yyyy) | Year to date figures for current period ended
(dd-mm-yyyy) | |
| Date of start of reporting period | 01-07-2026 | 01-04-2026 |
| Date of end of reporting period | 30-09-2026 | 30-09-2026 |
| Whether results are audited or unaudited | Unaudited | Unaudited |
| Nature of report standalone or consolidated | Standalone | Standalone |
| Part I | Blue color marked fields are non-mandatory.
For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column. |
| 1 | Income |
| Revenue from operations | 4952.76 | 9775.51 | |
| Other income | 16.86 | 38.74 |
| Total income | 4969.62 | 9814.25 |
| 2 | Expenses |
| (a) | Cost of materials consumed | 3145.35 | 6089.29 | |
| (b) | Purchases of stock-in-trade | 784.96 | 1540.47 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | -214.25 | -351.69 |
| (d) | Employee benefit expense | 208.82 | 412.69 |
| (e) | Finance costs | 20.77 | 59.2 |
| (f) | Depreciation, depletion and amortisation expense | 107.33 | 190.69 |
| (g) | Other Expenses |
| 1 | Other Expenses | 455.11 | 947.86 | |
| Total other expenses | 455.11 | 947.86 |
| Total expenses | 4508.09 | 8888.51 |
| 3 | Total profit before exceptional items and tax | 461.53 | 925.74 |
| 4 | Exceptional items | 0 | 0 |
| 5 | Total profit before tax | 461.53 | 925.74 |
| 6 | Tax expense |
| 7 | Current tax | 120.28 | 240.16 | |
| 8 | Deferred tax | -1.06 | 0.61 |
| 9 | Total tax expenses | 119.22 | 240.77 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0 | 0 |
| 11 | Net Profit Loss for the period from continuing operations | 342.31 | 684.97 |
| 12 | Profit (loss) from discontinued operations before tax | 0 | 0 |
| 13 | Tax expense of discontinued operations | 0 | 0 |
| 14 | Net profit (loss) from discontinued operation after tax | 0 | 0 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0 | 0 |
| 16 | Total profit (loss) for period | 342.31 | 684.97 |
| 17 | Other comprehensive income net of taxes | -0.13 | -0.25 |
| 18 | Total Comprehensive Income for the period | 342.18 | 684.72 |
| 19 | Total profit or loss, attributable to |
| Profit or loss, attributable to owners of parent | | | |
| Total profit or loss, attributable to non-controlling interests | | |
| 20 | Total Comprehensive income for the period attributable to |
| Comprehensive income for the period attributable to owners of parent | | | |
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | | |
| 21 | Details of equity share capital |
| Paid-up equity share capital | 110.79 | 110.79 | |
| Face value of equity share capital | 2 | 2 |
| 22 | Reserves excluding revaluation reserve | | |
| 23 | Earnings per share |
| i | Earnings per equity share for continuing operations |
| Basic earnings (loss) per share from continuing operations | 6.18 | 12.37 | |
| Diluted earnings (loss) per share from continuing operations | 6.18 | 12.36 |
| ii | Earnings per equity share for discontinued operations |
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 |
| iii | Earnings per equity share (for continuing and discontinued operations) |
| Basic earnings (loss) per share from continuing and discontinued operations | 6.18 | 12.37 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 6.18 | 12.36 |
| 24 | Debt equity ratio | | | Textual Information( 1) |
| 25 | Debt service coverage ratio | | | Textual Information( 2) |
| 26 | Interest service coverage ratio | | | Textual Information( 3) |
| 27 | Disclosure of notes on financial results | Textual Information(4) |
Statement of Asset and Liabilities |
| Particulars | Half Year ended (dd-mm-yyyy) |
| Date of start of reporting period | 01-04-2026 |
| Date of end of reporting period | 30-09-2026 |
| Whether results are audited or unaudited | Unaudited |
| Nature of report standalone or consolidated | Standalone |
| Assets |
| 1 | Non-current assets |
| Property, plant and equipment | 2095.2 |
| Capital work-in-progress | 786.72 |
| Investment property | |
| Goodwill | 10.6 |
| Other intangible assets | 442.43 |
| Intangible assets under development | |
| Biological assets other than bearer plants | |
| Investments accounted for using equity method | |
| Non-current financial assets | |
| Non-current investments | 5125.08 |
| Trade receivables, non-current | |
| Loans, non-current | 0 |
| Other non-current financial assets | |
| 1 | Other Financial Assets | 34.33 |
| 2 | | |
| 3 | | |
| 4 | | |
| 5 | | |
| Details of other non-current financial assets | |
| Total of other non-current financial assets | 34.33 |
| Total non-current financial assets | 5159.41 |
| Deferred tax assets (net) | 32.62 |
| Other non-current assets | |
| 1 | Income Tax Assets (Net) | 52.62 |
| 2 | Other non-current assets | 107.18 |
| 3 | | |
| 4 | | |
| 5 | | |
| Details of other non-current assets | |
| Total of other non-current assets | 159.8 |
| Total non-current assets | 8686.78 |
| 2 | Current assets | |
| Inventories | 2037.87 |
| Current financial asset | |
| Current investments | 300.22 |
| Trade receivables, current | 5243.63 |
| Cash and cash equivalents | 669.83 |
| Bank balance other than cash and cash equivalents | 38.98 |
| Loans, current | 409.8 |
| Other current financial assets | |
| 1 | Other financial assets | 265.46 |
| 2 | | |
| 3 | | |
| 4 | | |
| 5 | | |
| Details of other current financial assets | |
| Total of Other current financial assets | 265.46 |
| Total current financial assets | 6927.92 |
| Current tax assets (net) | |
| Other current assets | |
| 1 | Other current assets | 341.1 |
| 2 | | |
| 3 | | |
| 4 | | |
| 5 | | |
| Details of other current assets | |
| Total of other current assets | 341.1 |
| Total current assets | 9306.89 |
| 3 | Non-current assets classified as held for sale | |
| 4 | Regulatory deferral account debit balances and related deferred tax Assets | |
| Total assets | 17993.67 |
| Equity and liabilities | |
| 1 | Equity | |
| Equity attributable to owners of parent | |
| Equity share capital | 110.79 |
| Other equity | 12750.77 |
| Total equity attributable to owners of parent | 12861.56 |
| Non controlling interest | |
| Total equity | 12861.56 |
| 2 | Liabilities | |
| Non-current liabilities | |
| Non-current financial liabilities | |
| Borrowings, non-current | 46.11 |
| Trade Payables, non-current | |
| (A) Total outstanding dues of micro enterprises and small enterprises | |
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | |
| Total Trade payable | |
| Other non-current financial liabilities | |
| 1 | Lease Liabilities | 112.87 |
| 2 | | |
| 3 | | |
| 4 | | |
| 5 | | |
| Details of other non-current financial liabilities | |
| Total of other non-current financial liabilities | 112.87 |
| Total non-current financial liabilities | 158.98 |
| Provisions, non-current | 59.23 |
| Deferred tax liabilities (net) | |
| Deferred government grants, Non-current | |
| Other non-current liabilities | |
| 1 | | |
| 2 | | |
| 3 | | |
| 4 | | |
| 5 | | |
| Details of other non-current liabilities | |
| Total of other non-current liabilities | |
| Total non-current liabilities | 218.21 |
| Current liabilities | |
| Current financial liabilities | |
| Borrowings, current | 805.37 |
| Trade Payables, current | |
| (A) Total outstanding dues of micro enterprises and small enterprises | 231.52 |
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | 3426.09 |
| Total Trade payable | 3657.61 |
| Other current financial liabilities | |
| 1 | Lease Liabilities | 44.5 |
| 2 | Other financial liabilities | 191.65 |
| 3 | | |
| 4 | | |
| 5 | | |
| Details of other current financial liabilities | |
| Total of other current financial liabilities | 236.15 |
| Total current financial liabilities | 4699.13 |
| Other current liabilities | |
| 1 | Other current liabilities | 88.08 |
| 2 | | |
| 3 | | |
| 4 | | |
| 5 | | |
| Details of other current liabilities | |
| Total of other current liabilities | 88.08 |
| Provisions, current | 40.02 |
| Current tax liabilities (Net) | 86.67 |
| Deferred government grants, Current | |
| Total current liabilities | 4913.9 |
| 3 | Liabilities directly associated with assets in disposal group classified as held for sale | |
| 4 | Regulatory deferral account credit balances and related deferred tax liability | |
| Total liabilities | 5132.11 |
| Total equity and liabilities | 17993.67 |
| Disclosure of notes on assets and liabilities | |
Cash flow statement, indirect |
| Particulars | Half Year ended (dd-mm-yyyy) |
| Date of start of reporting period | 01-04-2026 |
| Date of end of reporting period | 30-09-2026 |
| Whether results are audited or unaudited | Unaudited |
| Nature of report standalone or consolidated | Standalone |
| Part I | Blue color marked fields are non-mandatory. |
| 1 | Statement of cash flows | |
| Cash flows from used in operating activities | |
| Profit before tax | 925.74 |
| 2 | Adjustments for reconcile profit (loss) | |
| Adjustments for finance costs | 63.24 |
| Adjustments for decrease (increase) in inventories | -240.6 |
| Adjustments for decrease (increase) in trade receivables, current | 71.44 |
| Adjustments for decrease (increase) in trade receivables, non-current | 0 |
| Adjustments for decrease (increase) in other current assets | 0 |
| Adjustments for decrease (increase) in other non-current assets | 0 |
| Adjustments for other financial assets, non-current | 0 |
| Adjustments for other financial assets, current | 0 |
| Adjustments for other bank balances | 0 |
| Adjustments for increase (decrease) in trade payables, current | 57.08 |
| Adjustments for increase (decrease) in trade payables, non-current | 0 |
| Adjustments for increase (decrease) in other current liabilities | 0 |
| Adjustments for increase (decrease) in other non-current liabilities | 0 |
| Adjustments for depreciation and amortisation expense | 190.69 |
| Adjustments for impairment loss reversal of impairment loss recognised in profit or loss | 0 |
| Adjustments for provisions, current | 23.5 |
| Adjustments for provisions, non-current | 0 |
| Adjustments for other financial liabilities, current | -0.09 |
| Adjustments for other financial liabilities, non-current | 0 |
| Adjustments for unrealised foreign exchange losses gains | 22.66 |
| Adjustments for dividend income | 0 |
| Adjustments for interest income | 18.61 |
| Adjustments for share-based payments | 8.59 |
| Adjustments for fair value losses (gains) | -4.73 |
| Adjustments for undistributed profits of associates | 0 |
| Other adjustments for which cash effects are investing or financing cash flow | -7.53 |
| Other adjustments to reconcile profit (loss) | 0 |
| Other adjustments for non-cash items | 0.49 |
| Share of profit and loss from partnership firm or association of persons or limited liability partnerships | 0 |
| Total adjustments for reconcile profit (loss) | 166.13 |
| Net cash flows from (used in) operations | 1091.87 |
| Dividends received | 0 |
| Interest paid | 0 |
| Interest received | 0 |
| Income taxes paid (refund) | 215.25 |
| Other inflows (outflows) of cash | 0 |
| Net cash flows from (used in) operating activities | 876.62 |
| 3 | Cash flows from used in investing activities | |
| Cash flows from losing control of subsidiaries or other businesses | 0 |
| Cash flows used in obtaining control of subsidiaries or other businesses | 0 |
| Other cash receipts from sales of equity or debt instruments of other entities | 54.28 |
| Other cash payments to acquire equity or debt instruments of other entities | 0 |
| Other cash receipts from sales of interests in joint ventures | 0 |
| Other cash payments to acquire interests in joint ventures | 0 |
| Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships | 0 |
| Cash payment for investment in partnership firm or association of persons or limited liability partnerships | 0 |
| Proceeds from sales of property, plant and equipment | 2.88 |
| Purchase of property, plant and equipment | 238.23 |
| Proceeds from sales of investment property | 0 |
| Purchase of investment property | 0 |
| Proceeds from sales of intangible assets | 0 |
| Purchase of intangible assets | 0 |
| Proceeds from sales of intangible assets under development | 0 |
| Purchase of intangible assets under development | 0 |
| Proceeds from sales of goodwill | 0 |
| Purchase of goodwill | 0 |
| Proceeds from biological assets other than bearer plants | 0 |
| Purchase of biological assets other than bearer plants | 0 |
| Proceeds from government grants | 0 |
| Proceeds from sales of other long-term assets | 0 |
| Purchase of other long-term assets | 0 |
| Cash advances and loans made to other parties | 0 |
| Cash receipts from repayment of advances and loans made to other parties | 0 |
| Cash payments for future contracts, forward contracts, option contracts and swap contracts | 0 |
| Cash receipts from future contracts, forward contracts, option contracts and swap contracts | 0 |
| Dividends received | 0 |
| Interest received | 14.01 |
| Income taxes paid (refund) | 0 |
| Other inflows (outflows) of cash | -0.75 |
| Net cash flows from (used in) investing activities | -167.81 |
| 4 | Cash flows from used in financing activities | |
| Proceeds from changes in ownership interests in subsidiaries | 0 |
| Payments from changes in ownership interests in subsidiaries | 0 |
| Proceeds from issuing shares | 4.57 |
| Proceeds from issuing other equity instruments | 0 |
| Payments to acquire or redeem entity's shares | 0 |
| Payments of other equity instruments | 0 |
| Proceeds from exercise of stock options | 0 |
| Proceeds from issuing debentures notes bonds etc | 0 |
| Proceeds from borrowings | 0 |
| Repayments of borrowings | 413.62 |
| Payments of lease liabilities | 26.57 |
| Dividends paid | 27.7 |
| Interest paid | 59.65 |
| Income taxes paid (refund) | 0 |
| Other inflows (outflows) of cash | 0 |
| Net cash flows from (used in) financing activities | -522.97 |
| Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes | 185.84 |
| 5 | Effect of exchange rate changes on cash and cash equivalents | |
| Effect of exchange rate changes on cash and cash equivalents | -2.49 |
| Net increase (decrease) in cash and cash equivalents | 183.35 |
| Cash and cash equivalents cash flow statement at beginning of period | 486.48 |
| Cash and cash equivalents cash flow statement at end of period | 669.83 |
Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter) |
| Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. |
| Sr. No. | Details of the party (listed entity /subsidiary) entering into the transaction | Details of the counterparty | Type of related party transaction | Details of other related party transaction | Value of the related party transaction as approved by the audit committee | Remarks on approval by audit committee | Value of the related party transaction ratified by the audit committee | Date of Audit Committee Meeting where the ratification was approved | Value of transaction during the reporting period | In case monies are due to either party as a result of the transaction | In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments | Details of the loans, inter-corporate deposits, advances or investments |
| Name | PAN | Name | PAN | Relationship of the counterparty with the listed entity or its subsidiary | Opening balance | Closing balance | Nature of indebtedness (loan/ issuance of debt/ any other etc.) | Details of other indebtedness | Cost | Tenure | Nature (loan/ advance/ intercorporate deposit/ investment) | Interest Rate (%) | Tenure | Secured/ unsecured | Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage) | Notes |
| 1 | Rossari Biotech Limited | | Sunil Chari | | Key Managerial Personnel | Remuneration | | | As per the Companies Act, 2013 and Shareholders' Approval | | | 2.84 | 0 | 0 | | | | | | | | | | |
| 2 | Rossari Biotech Limited | | Edward Menezes | | Key Managerial Personnel | Remuneration | | | As per the Companies Act, 2013 and Shareholders' Approval | | | 2.84 | 0 | 0 | | | | | | | | | | |
| 3 | Rossari Biotech Limited | | Mikhail Menezes | | Relative of Director | Remuneration | | | As per the Companies Act, 2013 and Shareholders' Approval | | | 5.37 | 0 | 0 | | | | | | | | | | |
| 4 | Rossari Biotech Limited | | Yash Chari | | Relative of Director | Remuneration | | | As per the Companies Act, 2013 and Shareholders' Approval | | | 0.58 | 0 | 0 | | | | | | | | | | |
| 5 | Rossari Biotech Limited | | Ketan Sablok | | Key Managerial Personnel | Remuneration | | | As per the Companies Act, 2013 and Shareholders' Approval | | | 14.69 | 0 | 0 | | | | | | | | | | |
| 6 | Rossari Biotech Limited | | Parul Gupta | | Key Managerial Personnel | Remuneration | | | As per the Companies Act, 2013 and Shareholders' Approval | | | 2.25 | 0 | 0 | | | | | | | | | | |
| 7 | Rossari Biotech Limited | | Rupesh Ruparelia | | Key Managerial Personnel | Remuneration | | | As per the Companies Act, 2013 and Shareholders' Approval | | | 3.03 | 0 | 0 | | | | | | | | | | |
| 8 | Rossari Biotech Limited | | Aseem Dhru | | Independent Director | Any other transaction | Sitting Fees | | NA | | | 0.5 | 0 | 0 | | | | | | | | | | |
| 9 | Rossari Biotech Limited | | Gurudas Aras | | Independent Director | Any other transaction | Sitting Fees | | NA | | | 0.9 | 0 | 0 | | | | | | | | | | |
| 10 | Rossari Biotech Limited | | Aparna Sharma | | Independent Director | Any other transaction | Sitting Fees | | NA | | | 0.4 | 0 | 0 | | | | | | | | | | |
| 11 | Rossari Biotech Limited | | Esha Achan | | Independent Director | Any other transaction | Sitting Fees | | NA | | | 0.9 | 0 | 0 | | | | | | | | | | |
| 12 | Rossari Biotech Limited | | Udeypaul Singh Gill | | Independent Director | Any other transaction | Sitting Fees | | NA | | | 0.4 | 0 | 0 | | | | | | | | | | |
| 13 | Rossari Biotech Limited | | Buzil Rossari Private Limited | | Wholly Owned Subsidiary Company | Sale of goods or services | | 750 | NA | | | 217.32 | 802.29 | 1012.65 | | | | | | | | | | |
| 14 | Rossari Biotech Limited | | Buzil Rossari Private Limited | | Wholly Owned Subsidiary Company | Purchase of goods or services | | 30 | NA | | | 0.99 | 0.23 | 11.34 | | | | | | | | | | |
| 15 | Rossari Biotech Limited | | Buzil Rossari Private Limited | | Wholly Owned Subsidiary Company | Loan | | 500 | NA | | | 0 | 240 | 240 | | | | | Loan | 8.00% | On Demand | Unsecured | General Business Requirement | |
| 16 | Rossari Biotech Limited | | Buzil Rossari Private Limited | | Wholly Owned Subsidiary Company | Interest received | | 500 | NA | | | 9.68 | 0 | 0 | | | | | | | | | | |
| 17 | Rossari Biotech Limited | | Buzil Rossari Private Limited | | Wholly Owned Subsidiary Company | Any other transaction | Employee Cost - Recovery | 100 | NA | | | 7.99 | 0 | 0 | | | | | | | | | | |
| 18 | Rossari Biotech Limited | | Buzil Rossari Private Limited | | Wholly Owned Subsidiary Company | Any other transaction | Employee Cost - Reimbursement | 100 | NA | | | 10.05 | 0 | 0 | | | | | | | | | | |
| 19 | Rossari Biotech Limited | | Buzil Rossari Private Limited | | Wholly Owned Subsidiary Company | Any other transaction | Recovery of Expenses | 100 | NA | | | 4.39 | 0 | 0 | | | | | | | | | | |
| 20 | Rossari Biotech Limited | | Rossari Consumer Products Private Limited | | Wholly Owned Subsidiary Company | Sale of goods or services | | 600 | NA | | | 101.64 | 316.09 | 375.92 | | | | | | | | | | |
| 21 | Rossari Biotech Limited | | Rossari Consumer Products Private Limited | | Wholly Owned Subsidiary Company | Any other transaction | Employee Cost - Recovery | 50 | NA | | | 1.01 | 0 | 0 | | | | | | | | | | |
| 22 | Rossari Biotech Limited | | Rossari Consumer Products Private Limited | | Wholly Owned Subsidiary Company | Any other transaction | Recovery of Expenses | 50 | NA | | | 0.86 | 0 | 0 | | | | | | | | | | |
| 23 | Rossari Biotech Limited | | Tristar Intermediates Private Limited | | Wholly Owned Subsidiary Company | Sale of goods or services | | 150 | NA | | | 27.64 | 101.29 | 25.97 | | | | | | | | | | |
| 24 | Rossari Biotech Limited | | Tristar Intermediates Private Limited | | Wholly Owned Subsidiary Company | Any other transaction | Commission Income | | NA | | | 10.03 | 0 | 0 | | | | | | | | | | |
| 25 | Rossari Biotech Limited | | Tristar Intermediates Private Limited | | Wholly Owned Subsidiary Company | Purchase of goods or services | | 2500 | NA | | | 1264.21 | 1040.85 | 733.59 | | | | | | | | | | |
| 26 | Rossari Biotech Limited | | Tristar Intermediates Private Limited | | Wholly Owned Subsidiary Company | Purchase of fixed assets | | 25 | NA | | | 1.14 | 0 | 0 | | | | | | | | | | |
| 27 | Rossari Biotech Limited | | Tristar Intermediates Private Limited | | Wholly Owned Subsidiary Company | Any other transaction | Employee Cost - Recovery | 100 | NA | | | 26.77 | 0 | 0 | | | | | | | | | | |
| 28 | Rossari Biotech Limited | | Tristar Intermediates Private Limited | | Wholly Owned Subsidiary Company | Any other transaction | Recovery of Expenses | 100 | NA | | | 1.34 | 0 | 0 | | | | | | | | | | |
| 29 | Rossari Biotech Limited | | Unitop Chemicals Private Limited | | Subsidiary Company | Sale of goods or services | | 2880 | NA | | | 380.75 | 467.29 | 377.34 | | | | | | | | | | |
| 30 | Rossari Biotech Limited | | Unitop Chemicals Private Limited | | Subsidiary Company | Any other transaction | Commission Income | 2880 | NA | | | 81.22 | 0 | 0 | | | | | | | | | | |
| 31 | Rossari Biotech Limited | | Unitop Chemicals Private Limited | | Subsidiary Company | Sale of fixed assets | | 50 | NA | | | 0.83 | 0 | 0 | | | | | | | | | | |
| 32 | Rossari Biotech Limited | | Unitop Chemicals Private Limited | | Subsidiary Company | Purchase of goods or services | | 7000 | NA | | | 2434.29 | 1308.75 | 1312.31 | | | | | | | | | | |
| 33 | Rossari Biotech Limited | | Unitop Chemicals Private Limited | | Subsidiary Company | Purchase of fixed assets | | 50 | NA | | | 2.05 | 0 | 0 | | | | | | | | | | |
| 34 | Rossari Biotech Limited | | Unitop Chemicals Private Limited | | Subsidiary Company | Any other transaction | Employee Cost - Recovery | 300 | NA | | | 66.82 | 0 | 0 | | | | | | | | | | |
| 35 | Rossari Biotech Limited | | Unitop Chemicals Private Limited | | Subsidiary Company | Any other transaction | Recovery of Expenses | 300 | NA | | | 11.68 | 0 | 0 | | | | | | | | | | |
| 36 | Rossari Biotech Limited | | Romakk Chemicals Private Limited | | Associate | Sale of goods or services | | 60 | NA | | | 0.87 | 2.08 | 2.31 | | | | | | | | | | |
| 37 | Rossari Biotech Limited | | Romakk Chemicals Private Limited | | Associate | Purchase of goods or services | | 400 | NA | | | 136.95 | 90.19 | 131.39 | | | | | | | | | | |
| 38 | Rossari Biotech Limited | | Romakk Chemicals Private Limited | | Associate | Any other transaction | Employee Cost - Recovery | 20 | NA | | | 2.67 | 0 | 0 | | | | | | | | | | |
| 39 | Rossari Biotech Limited | | Romakk Chemicals Private Limited | | Associate | Any other transaction | Recovery of Expenses | | NA | | | 0.33 | 0 | 0 | | | | | | | | | | |
| 40 | Rossari Biotech Limited | | K. K. Chempro (India) Private Limited | | Related Party to Romakk Chemicals Private
Limited (subsidiary company) | Any other transaction | Receivables Ac | | NA | | | 0 | 0.01 | 0.01 | | | | | | | | | | |
| 41 | Rossari Biotech Limited | | INSAI CHEMPLAST
(Formerly known as K K CHEMICAL INDUSTRIES) | | Related Party to Romakk Chemicals Private
Limited (subsidiary company) | Any other transaction | Payable Ac (Dr.Bal) | | NA | | | 0 | 0.05 | 0.05 | | | | | | | | | | |
| 42 | Rossari Biotech Limited | | McCoy Performance Silicones Private Limited | | Related Party to Romakk Chemicals Private
Limited (subsidiary company) | Any other transaction | Payable Ac (Dr.Bal) | | NA | | | 0 | 0.01 | 0.01 | | | | | | | | | | |
| 43 | Rossari Biotech Limited | | Rossari Global FZCO (Formerly known as Rossari Global DMCC) | | Wholly Owned Subsidiary Company | Loan | | 360 | NA | | | 0 | 117.59 | 120.04 | | | | | Loan | 10.00% | On Demand | Unsecured | General Business Requirement | |
| 44 | Rossari Biotech Limited | | Rossari Global FZCO (Formerly known as Rossari Global DMCC) | | Wholly Owned Subsidiary Company | Interest received | | 36 | NA | | | 5.99 | 15.79 | 17.99 | | | | | | | | | | |
| 45 | Rossari Biotech Limited | | Rossari Global FZCO (Formerly known as Rossari Global DMCC) | | Wholly Owned Subsidiary Company | Any other transaction | Recovery of Expenses | 10 | NA | | | 0.25 | 2.34 | 3.33 | | | | | | | | | | |
| 46 | Rossari Biotech Limited | | Rossari Global FZCO (Formerly known as Rossari Global DMCC) | | Wholly Owned Subsidiary Company | Any other transaction | Corporate Guarantee Given | 168 | NA | | | 0 | 149.08 | 151.17 | | | | | | | | | | |
| 47 | Rossari Biotech Limited | | Rossari Global FZCO (Formerly known as Rossari Global DMCC) | | Wholly Owned Subsidiary Company | Any other transaction | Corporate Guarantee Commission Income | 1.7 | NA | | | 0.75 | 0 | 0 | | | | | | | | | | |
| 48 | Rossari Biotech Limited | | Rossari Biotech Trading FZE | | Step Down Wholly Owned Subsidiary | Sale of goods or services | | 4000 | NA | | | 1496.43 | 378.68 | 913.07 | | | | | | | | | | |
| 49 | Rossari Biotech Limited | | Rossari Biotech Trading FZE | | Step Down Wholly Owned Subsidiary | Any other transaction | Recovery of Expenses | 5 | NA | | | 0.94 | 0 | 0 | | | | | | | | | | |
| 50 | Rossari Biotech Limited | | Rossari Biotech Trading FZE | | Step Down Wholly Owned Subsidiary | Any other transaction | Corporate Guarantee Given | 672 | NA | | | 0 | 596.32 | 604.67 | | | | | | | | | | |
| 51 | Rossari Biotech Limited | | Rossari Biotech Trading FZE | | Step Down Wholly Owned Subsidiary | Any other transaction | Corporate Guarantee Commission Income | 67 | NA | | | 3.01 | 0 | 0 | | | | | | | | | | |
| 52 | Rossari Biotech Limited | | Unistar Thai Company Limited | | Step Down Wholly Owned Subsidiary | Sale of goods or services | | 1080 | NA | | | 8.9 | 29.17 | 23.13 | | | | | | | | | | |
| 53 | Rossari Biotech Limited | | Unistar Thai Company Limited | | Step Down Wholly Owned Subsidiary | Purchase of goods or services | | 550 | NA | | | 2.72 | 0 | 0 | | | | | | | | | | |
| 54 | Rossari Biotech Limited | | Unistar Thai Company Limited | | Step Down Wholly Owned Subsidiary | Any other transaction | Recovery of Expenses | 10 | NA | | | 0.07 | 0 | 0 | | | | | | | | | | |
| 55 | Rossari Biotech Limited | | Unistar Thai Company Limited | | Step Down Wholly Owned Subsidiary | Any other transaction | Corporate Guarantee Given | 840 | NA | | | 0 | 745.4 | 755.84 | | | | | | | | | | |
| 56 | Rossari Biotech Limited | | Unistar Thai Company Limited | | Step Down Wholly Owned Subsidiary | Any other transaction | Corporate Guarantee Commission Income | 8.4 | NA | | | 3.76 | 0 | 0 | | | | | | | | | | |
| 57 | Rossari Biotech Limited | | K K Chem India Private Limited | | Related Party to Romakk Chemicals Private
Limited (subsidiary company) | Purchase of goods or services | | 50 | NA | | | 2.14 | 0.49 | 0.43 | | | | | | | | | | |
| 58 | Rossari Biotech Limited | | Rossari International Limited Company | | Wholly Owned Subsidiary Company | Loan | | 1000 | NA | | | 0 | 25.03 | 25.57 | | | | | Loan | 7.22% | On Demand | Unsecured | General Business Requirement | |
| 59 | Rossari Biotech Limited | | Rossari International Limited Company | | Wholly Owned Subsidiary Company | Interest received | | 100 | NA | | | 0.89 | 0.77 | 1.71 | | | | | | | | | | |
| 60 | Rossari Biotech Limited | | Rossari International Limited Company | | Wholly Owned Subsidiary Company | Any other transaction | Recovery of Expenses | 100 | NA | | | 7.82 | 7.77 | 15.59 | | | | | | | | | | |
| 61 | Unitop Chemicals Private Limited | | Gurudas Aras | | Independent Director | Any other transaction | Sitting Fees | | NA | | | 0.15 | 0 | 0 | | | | | | | | | | |
| 62 | Unitop Chemicals Private Limited | | Aparna Sharma | | Independent Director | Any other transaction | Sitting Fees | | NA | | | 0.13 | 0 | 0 | | | | | | | | | | |
| 63 | Unitop Chemicals Private Limited | | Tristar Intermediates Private Limited | | Fellow Subsidiary | Sale of goods or services | | 500 | NA | | | 343.27 | 251.01 | 321.31 | | | | | | | | | | |
| 64 | Unitop Chemicals Private Limited | | Tristar Intermediates Private Limited | | Fellow Subsidiary | Purchase of goods or services | | 500 | NA | | | 287.85 | 75.43 | 6.97 | | | | | | | | | | |
| 65 | Unitop Chemicals Private Limited | | Buzil Rossari Private Limited | | Fellow Subsidiary | Purchase of goods or services | | 10 | NA | | | 0 | 0.55 | 1.2 | | | | | | | | | | |
| 66 | Unitop Chemicals Private Limited | | Buzil Rossari Private Limited | | Fellow Subsidiary | Any other transaction | Purchase of fixed assets | 10 | NA | | | 0.25 | 0 | 0 | | | | | | | | | | |
| 67 | Unitop Chemicals Private Limited | | Buzil Rossari Private Limited | | Fellow Subsidiary | Any other transaction | Reimbursement | 5 | NA | | | 2.01 | 0 | 0 | | | | | | | | | | |
| 68 | Unitop Chemicals Private Limited | | Hextar Unitop SDN.BHD. | | Joint Venture | Sale of goods or services | | 60 | NA | | | 25.79 | 2.99 | 7.25 | | | | | | | | | | |
| 69 | Unitop Chemicals Private Limited | | Romakk Chemicals Private Limited | | Associate of Holding Company | Sale of goods or services | | 12.5 | NA | | | 1.24 | 0 | 0 | | | | | | | | | | |
| 70 | Unitop Chemicals Private Limited | | Romakk Chemicals Private Limited | | Associate of Holding Company | Purchase of goods or services | | 150 | NA | | | 9.22 | 0 | 10.87 | | | | | | | | | | |
| 71 | Unitop Chemicals Private Limited | | Glad Properties (India) Private Limited | | Promoter Group Company | Any other transaction | Rent | 2.4 | NA | | | 1.02 | 0.22 | 0 | | | | | | | | | | |
| 72 | Tristar Intermediates Private Limited | | Gurudas Aras | | Independent Director | Any other transaction | Sitting Fees | | NA | | | 0.05 | 0 | 0 | | | | | | | | | | |
| 73 | Tristar Intermediates Private Limited | | Buzil Rossari Private Limited | | Fellow Subsidiary | Purchase of goods or services | | 10 | NA | | | 0 | 0.19 | 0.38 | | | | | | | | | | |
| 74 | Tristar Intermediates Private Limited | | Buzil Rossari Private Limited | | Fellow Subsidiary | Any other transaction | Reimbursement Expenses (Employee) | 5 | NA | | | 0.63 | 0 | 0 | | | | | | | | | | |
| 75 | Tristar Intermediates Private Limited | | Romakk Chemicals Private Limited | | Fellow Subsidiary | Sale of goods or services | | 12.5 | NA | | | 0 | 0.01 | 0 | | | | | | | | | | |
| 76 | Buzil Rossari Private Limited | | Rockdude Impex Private Limited | | Related Party of Fellow Subsidiary | Sale of goods or services | | 1000 | NA | | | 119.91 | 58.55 | 56.04 | | | | | | | | | | |
| 77 | Buzil Rossari Private Limited | | Rockdude Impex Private Limited | | Related Party of Fellow Subsidiary | Purchase of goods or services | | 1000 | NA | | | 148.82 | -466.43 | -223.02 | | | | | | | | | | |
| 78 | Romakk Chemicals Private Limited | | Nitin Sethi | | Key Managerial Personnel | Remuneration | | 5 | NA | | | 2.5 | 0 | 0 | | | | | | | | | | |
| 79 | Romakk Chemicals Private Limited | | Amit Malhotra | | Key Managerial Personnel | Remuneration | | 2.4 | NA | | | 1.2 | 0 | 0 | | | | | | | | | | |
| 80 | Romakk Chemicals Private Limited | | Gurudas Aras | | Independent Director | Any other transaction | Sitting Fees | | NA | | | 0.13 | 0 | 0 | | | | | | | | | | |
| 81 | Romakk Chemicals Private Limited | | Esha Achan | | Independent Director | Any other transaction | Sitting Fees | | NA | | | 0.13 | 0 | 0 | | | | | | | | | | |
| 82 | Romakk Chemicals Private Limited | | K K Chem India Private Limited | | Enterprises on which Director or their relatives are able to exercise significant influence | Sale of goods or services | | 1 | NA | | | 0 | 0.4 | 0 | | | | | | | | | | |
| 83 | Romakk Chemicals Private Limited | | K K Chem India Private Limited | | Enterprises on which Director or their relatives are able to exercise significant influence | Purchase of goods or services | | 50 | NA | | | 14.15 | 2.82 | 8.73 | | | | | | | | | | |
| 84 | Romakk Chemicals Private Limited | | Nitin Sethi (HUF) | | Enterprises on which Director or their relatives are able to exercise significant influence | Any other transaction | Rent | 2.1 | NA | | | 1.05 | 0.07 | 0.16 | | | | | | | | | | |
| 85 | Romakk Chemicals Private Limited | | Sumant Agrawal (HUF) | | Enterprises on which Director or their relatives are able to exercise significant influence | Any other transaction | Rent | 2.1 | NA | | | 1.05 | 0.08 | 0.19 | | | | | | | | | | |
| 86 | Rossari Global FZCO (Formerly known as Rossari Global DMCC) | | Sunil Chari | | Director | Remuneration | | | As per the Companies Act, 2013 | | | 4.88 | 0 | 0 | | | | | | | | | | |
| 87 | Rossari Global FZCO (Formerly known as Rossari Global DMCC) | | Yashika Chari | | Relative of Director | Remuneration | | | As per the Companies Act, 2013 | | | 4.46 | 0 | 0 | | | | | | | | | | |
| 88 | Rossari Global FZCO (Formerly known as Rossari Global DMCC) | | Rupesh Ruparelia | | Manager | Remuneration | | | As per SEBI LODR,2015 | | | 0.93 | 0 | 0 | | | | | | | | | | |
| 89 | Rossari Global FZCO (Formerly known as Rossari Global DMCC) | | Rossari Biotech Trading FZE | | Wholly Owned Subsidiary Company | Loan | | 95.98 | NA | | | 10.36 | 25.56 | 15.66 | | | | | Loan | 10.00% | On Demand | Unsecured | General Business Requirement | |
| 90 | Rossari Global FZCO (Formerly known as Rossari Global DMCC) | | Rossari Biotech Trading FZE | | Wholly Owned Subsidiary Company | Interest received | | 9.6 | NA | | | 1.01 | 0.73 | 0.26 | | | | | | | | | | |
| 91 | Rossari Global FZCO (Formerly known as Rossari Global DMCC) | | Unistar Thai Company Limited | | Wholly Owned Subsidiary Company | Loan | | 86.38 | NA | | | 0 | 28.12 | 28.7 | | | | | | | | | | |
| 92 | Rossari Global FZCO (Formerly known as Rossari Global DMCC) | | Unistar Thai Company Limited | | Wholly Owned Subsidiary Company | Interest received | | 8.6 | NA | | | 1.43 | 0.75 | 0.48 | | | | | | | | | | |
| 93 | Rossari International Limited Company | | Rupesh Ruparelia | | Manager | Remuneration | | | As per SEBI LODR,2015 | | | 0.76 | 0 | 0 | | | | | | | | | | |
| 94 | Rossari Biotech Trading FZE | | Edward Menezes | | Director | Remuneration | | | As per the Companies Act, 2013 | | | 6.19 | 0 | 0 | | | | | | | | | | |
| 95 | Rossari Biotech Trading FZE | | Yash Chari | | Director | Remuneration | | | As per the Companies Act, 2013 | | | 4.7 | 0 | 0 | | | | | | | | | | |
| 96 | Rossari Biotech Limited | | Prasad Gadkari | | Director of Subsidiary | Remuneration | | | As per the Companies Act, 2013 and SEBI LODR,2015 | | | 6.92 | 0 | 0 | | | | | | | | | | |
| 97 | Rossari Biotech Limited | | Pravin Deokar | | Director of Subsidiary | Remuneration | | | As per the Companies Act, 2013 and SEBI LODR,2015 | | | 1.39 | 0 | 0 | | | | | | | | | | |
| 98 | Tristar Intermediates Private Limited | | Sanjay Marballi | | Director | Remuneration | | | As per the Companies Act, 2013 and SEBI LODR,2015 | | | 6.76 | 0 | 0 | | | | | | | | | | |
| 99 | Tristar Intermediates Private Limited | | Krishna Kumar Tiwari | | Director | Remuneration | | | As per the Companies Act, 2013 and SEBI LODR,2015 | | | 1.25 | 0 | 0 | | | | | | | | | | |
| Total value of transaction during the reporting period | | | | | | | | | | | | 7383.48 | | | | | | | | | | | | |